Compare AbCellera Biologics Inc (ABCL) vs Gogoro Inc (GGR) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

GGR trades at $3.94, down 0.51% today, with a bearish technical signal and negative profitability. The company reported a net loss of $79.97 million on $281.48 million revenue for 2025, though operating cash flow improved to $35.90 million. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvements and growth initiatives.

The outlook remains challenging due to persistent losses and negative ROE, but low valuation multiples and projected cash flow improvements offer potential upside if execution improves. Key risks include sustained unprofitability and competitive pressures in the mobility sector.